A Phase 3 interventional study of Diosmin and Placebo in Non Alcoholic Steatohepatitis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by Tanta University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University — 6 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Tanta University.
Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 8th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →6 of the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18–65
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
Tanta University · Sites in Egypt
Ages 18–60
Tanta University · Sites in Egypt
Ages 18–60
Tanta University
Ages 18+
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 2
First in 2019; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 58 across the 12 interventional studies, 500 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Non-alcoholic Fatty Liver Disease by Tanta University that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07900100Phase 3Tanta UniversityEvaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients. | 2027-06-20 |
| NCT07900087Phase 3Tanta UniversityEvaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients | 2027-08-01 |
| NCT06863376Tanta UniversityEvaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients | 2027-03-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, controlled study evaluating diosmin tablets administered daily for 3 months. The purpose of the study is to evaluate the efficacy and safety of diosmin on non-diabetic patients with non-alcoholic steatohepatitis.
The aim of the study is to test the implication of diosmin in fatty liver disease through evaluation of its efficacy and safety in non-diabetic patients with nonalcoholic steatohepatitis (NASH).
Patients and Methods:
This study will be a randomized double-blind placebo-controlled parallel study that will involve 48 non-diabetic patients with confirmed diagnosis of NASH. The patients will be recruited from outpatient Clinic of the internal medicine department, Tanta University Hospital, Tanta, Egypt. The diagnosis of NASH will be confirmed by imaging technique (increased liver echogenicity, stronger echoes in the hepatic parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins), mild to moderate elevation in aminotransferase activities (>2 but \<5 times upper limit of normal), hepatic steatosis index (HIS) >36, HAIR score (hypertension, alanine aminotransferase level, insulin resistance) of 2 or 3 and cytokeratin-18 level >240 IU/L. The patients will be randomized in a 1:1 ratio by a neutral researcher using sealed envelopes methods with assignment codes for each available allocation to receive either diosmin 600 mg twice daily (Diosmin group; n = 24) or placebo twice daily (Placebo group; n = 24). The study duration will be 12 weeks.
Friedewald formula17 as follows:
[LDL-C=TC- HDL-C- (TG÷5)] provided that TG level is less than 400 mg/dl.
HSI is calculated by the following formula:
8 × (ALT/AST ratio) + BMI + 2 if female and + 2 if diabetic (0 since the study will be conducted on non-diabetic).
Prescience of the 3 items indicates HAIR score=3.
/L) ×√ ALT (IU/l)].
Aspartate transaminase-to-platelet ratio index (APRI).22 APRI =AST (IU/l)/(upper limit of normal) X 100 /platelet count (109
/L).
NAFLD fibrosis score (NFS) which depends on 7 parameters including age, BMI, diabetes, AST, ALT, platelets count, and albumin concentration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Diosmin group; n = 24):will receive 600 mg twice daily
Drug: Diosmin
placebo group n=24 :will receive placebo twice daily
Drug: Placebo
diosmin 600mg twice daily
twice daily
the change in ultrasound including NAFLD fibrosis scor
The change in ultrasound through decreasing liver echogenicity, Lower echoes in the hepatic parenchyma, no vessel blurring, and decrease narrowing of the lumen of the hepatic veins Ultrasonography Fatty Liver Indicator (US-FLI) \<2
Time frame: at baseline then after 3 months
The change in fibrosis risk score
Score \<-1.455 predicts absence of significant fibrosis (F0-F2)
Time frame: at baseline then after 3 months
The secondary outcome is the change in biological biomarkers and other measured parameters
The change in liver panel
Time frame: at baseline then after 3 months
secondary outcome is the change in biological biomarkers and other measured parameters
The change in the Homeostasis Model Assessment-insulin resistance (HOMA-IR)
Time frame: at baseline then after 3 months
secondary outcome is the change in biological biomarkers and other measured parameters
The change in biological parameters (MDA, TNF-α, and TGF-β1)
Time frame: at baseline then after 3 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2023; primary completion for Oct 2023, 3 months later.
Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diosmin
Non-alcoholic Fatty Liver Disease →